Examination Report |
1 | TM-A(TRADE MARKS APPLICATION) | 20 Jan 2022 |
10 | Authorization Letter | 09 Feb 2024 |
11 | Journal Copy | 24 Jun 2024 |
12 | Certificate | 11 Jul 2024 |
2 | Reply to Exam Report (MIS-R) | 18 Feb 2022 |
3 | Reply to Exam Report (MIS-R) | 21 Feb 2022 |
4 | TM-M(REQUEST SUBMITTING AUTHORISATION OF AGENT) | 27 Sep 2022 |
5 | TM-M(REQUEST SUBMITTING AUTHORISATION OF AGENT) | 03 Mar 2023 |
6 | Documents in support of Show cause Hearing (SCH) | 20 Jul 2023 |
7 | Evedence Affidavit on use of Trade Mark (TLA) | 28 Jul 2023 |
8 | Reply to Exam Report (MIS-R) | 04 Aug 2023 |
9 | Documents in support of Show cause Hearing (SCH) | 07 Feb 2024 |
1 | EXAMINATION REPORT | 13046650 | 18 Feb 2022 | |
2 | Hearing Notice (Show Cause) | 17098770 | 10 Jan 2024 | |
3 | Tribunal Accepted Notice for : 5292738 | 17395385 | 6547415 | 13 Feb 2024 |
The application for Rezfuran was made on 20 January 2022.
The trademark applicant for Rezfuran is Abbott Healthcare Private Limited.
Rezfuran is applied in class(es) 5.
Application for Rezfuran is on Registered stage.
Application Id allotted to Rezfuran is 5292738.
Trademark agent or attorney for the application is Zeusip Advocates Llp.
Rezfuran filed with the Intellectual property office as a WORD.